Oncopeptides AB

OSTO:ONCO (Sweden)  
kr 6.66 (+26.18%) Mar 27
At Loss
P/B:
4.52
Market Cap:
kr 602.33M ($ 56.26M)
Enterprise V:
kr 476.71M ($ 44.53M)
Volume:
1.94M
Avg Vol (2M):
440.61K
Also Trade In:
Volume:
1.94M
At Loss
Avg Vol (2M):
440.61K

Business Description

Description
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.
Name Current Vs Industry Vs History
Cash-To-Debt 2.16
Equity-to-Asset 0.45
Debt-to-Equity 0.81
Debt-to-EBITDA -0.42
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.01
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 80.86
9-Day RSI 67.31
14-Day RSI 59.71
6-1 Month Momentum % -39.77
12-1 Month Momentum % -54.16

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.68
Quick Ratio 6.63
Cash Ratio 5.59
Days Sales Outstanding 373.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -17.7
Shareholder Yield % -12.57

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 106.09
Operating Margin % -896.8
Net Margin % -850.76
FCF Margin % -991.12
ROE % -106.72
ROA % -70.8
ROIC % -386.77
ROC (Joel Greenblatt) % -2177.59
ROCE % -88.58

Financials (Next Earnings Date:2024-05-03)

OSTO:ONCO's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Oncopeptides AB Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 30.443
EPS (TTM) (kr) -2.87
Beta -1.64
Volatility % 53.57
14-Day RSI 59.71
14-Day ATR (kr) 0.72891
20-Day SMA (kr) 5.39265
12-1 Month Momentum % -54.16
52-Week Range (kr) 4 - 11.935
Shares Outstanding (Mil) 90.44

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Oncopeptides AB Filings

Filing Date Document Date Form
No Filing Data

Oncopeptides AB Stock Events

Financials Calendars
Event Date Price(kr)
No Event Data

Oncopeptides AB Frequently Asked Questions

What is Oncopeptides AB(OSTO:ONCO)'s stock price today?
The current price of OSTO:ONCO is kr6.66. The 52 week high of OSTO:ONCO is kr11.94 and 52 week low is kr4.00.
When is next earnings date of Oncopeptides AB(OSTO:ONCO)?
The next earnings date of Oncopeptides AB(OSTO:ONCO) is 2024-05-03.
Does Oncopeptides AB(OSTO:ONCO) pay dividends? If so, how much?
Oncopeptides AB(OSTO:ONCO) does not pay dividend.

Press Release

Subject Date
No Press Release